Articles related to LYMPHOMA

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

A Swedish case-control study identified a 21% increased risk of malignant lymphoma in individuals with tattoos compared to controls, prompting the need for further research into tattoo ink composition and potential long-term health effects.

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

Explore the profound impact of Social Determinants of Health on mantle cell lymphoma outcomes and the potential of novel therapies in reducing these disparities.

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.

With a complete metabolic response rate of 82.1% after just four cycles of induction, this new regimen could change how we approach treatment for young patients with low risk, relapsed classical Hodgkin lymphoma.